TaiMed Biologics Financials
| 4147 Stock | TWD 90.10 0.70 0.78% |
TaiMed |
Understanding current and past TaiMed Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of TaiMed Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in TaiMed Biologics' assets may result in an increase in income on the income statement.
The data published in TaiMed Biologics' official financial statements typically reflect TaiMed Biologics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving TaiMed Biologics' quantitative information. For example, before you start analyzing numbers published by TaiMed accountants, it’s essential to understand TaiMed Biologics' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in TaiMed Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of TaiMed Biologics. Check TaiMed Biologics' Beneish M Score to see the likelihood of TaiMed Biologics' management manipulating its earnings.
TaiMed Biologics Stock Summary
TaiMed Biologics competes with Taiwan Semiconductor, Hon Hai, MediaTek, Chunghwa Telecom, and Formosa Petrochemical. TaiMed Biologics Inc., a biotechnology company, develops health-care products. The company was founded in 2007 and is based in Taipei City, Taiwan. TAIMED BIOLOGICS operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.| Instrument | Taiwan Stock View All |
| Exchange | Taiwan OTC Exchange |
| ISIN | TW0004147004 |
| Business Address | No 607, Ruiguang |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.taimedbiologics.com |
| Phone | 886 2 2658 0058 |
| Currency | TWD - New Taiwan Dollar |
You should never invest in TaiMed Biologics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of TaiMed Stock, because this is throwing your money away. Analyzing the key information contained in TaiMed Biologics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
TaiMed Biologics Key Financial Ratios
There are many critical financial ratios that TaiMed Biologics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that TaiMed Biologics reports annually and quarterly.| Return On Equity | -0.18 | |||
| Return On Asset | -0.062 | |||
| Target Price | 88.0 | |||
| Number Of Employees | 37 | |||
| Beta | 0.51 |
TaiMed Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining TaiMed Biologics's current stock value. Our valuation model uses many indicators to compare TaiMed Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across TaiMed Biologics competition to find correlations between indicators driving TaiMed Biologics's intrinsic value. More Info.TaiMed Biologics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the TaiMed Biologics' earnings, one of the primary drivers of an investment's value.TaiMed Biologics Systematic Risk
TaiMed Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. TaiMed Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on TaiMed Biologics correlated with the market. If Beta is less than 0 TaiMed Biologics generally moves in the opposite direction as compared to the market. If TaiMed Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one TaiMed Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of TaiMed Biologics is generally in the same direction as the market. If Beta > 1 TaiMed Biologics moves generally in the same direction as, but more than the movement of the benchmark.
TaiMed Biologics June 10, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of TaiMed Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of TaiMed Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of TaiMed Biologics based on widely used predictive technical indicators. In general, we focus on analyzing TaiMed Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build TaiMed Biologics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 13.82 | |||
| Value At Risk | (3.12) | |||
| Potential Upside | 2.79 |
Additional Tools for TaiMed Stock Analysis
When running TaiMed Biologics' price analysis, check to measure TaiMed Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TaiMed Biologics is operating at the current time. Most of TaiMed Biologics' value examination focuses on studying past and present price action to predict the probability of TaiMed Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TaiMed Biologics' price. Additionally, you may evaluate how the addition of TaiMed Biologics to your portfolios can decrease your overall portfolio volatility.